- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
An infographic published by PharmaPro illustrates the problem of drug shortages in the United States. With a 74% increase in drug shortages over the last five years, and an average of 12 years to get a new drug approved, PharmaPro writes that “the U.S. has a drug shortage problem that refuses to go away.” According …
An infographic published by PharmaPro illustrates the problem of drug shortages in the United States. With a 74% increase in drug shortages over the last five years, and an average of 12 years to get a new drug approved, PharmaPro writes that “the U.S. has a drug shortage problem that refuses to go away.”
According to the infographic:
Though the FDA has gotten better at stopping new shortages in recent years, the total number of drugs in short supply remains stubbornly high. Why the hold-ups? Most experts point to recall troubles, aging processing equipment, the FDA’s lengthy approval process for new drugs, or dwindling supplies of raw or bulk materials needed to produce certain drugs. But according to a 2011 study, manufacturing problems only accounted for 23 percent of drug shortages, while supply/demand issues were blamed for 13 percent. Around half of shortages were caused by “unknown” factors.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.